Amphastar Pharmaceuticals, Inc.

Amphastar is headquartered in the United States and generates most of its business through U.S.-based commercial and manufacturing operations. The company also operates a manufacturing facility in China, where it produces certain starting materials and APIs and plans further expansion. Management highlighted that all finished products and four APIs are manufactured in the United States, but the company still imports APIs, starting materials, and components from multiple countries, creating supply-chain exposure. Geography matters because the business depends on both domestic production capacity and cross-border sourcing, while tariffs, trade policy, and political conditions can affect cost and continuity. Foreign subsidiaries held cash outside the U.S., which limits immediate access to that liquidity for parent-company needs.

Amphastar faces meaningful concentration and execution risk around a relatively small set of commercial products, where sales of glucagon, epinephrine, and BAQSIMI® can fluctuate with competition and supply availability. The company also has material manufacturing and geopolitical exposure in China, where disruption, political unrest, tariffs, or regulatory changes could affect APIs and starting materials. Because the business depends on regulated sterile manufacturing, FDA and DEA compliance failures, plant interruptions, or quality issues could materially disrupt supply and sales. In addition, the company is exposed to pricing pressure from wholesalers, distributor fees, prompt-pay discounts, and patient assistance programs, while cyber and data-security incidents could impair operations, clinical data, or third-party relationships.